Direct sGC activation bypasses no scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction

Antioxidants and Redox Signaling

Volumn 19, Issue 18, 2013, Pages 2232-2243

  Raat, Nicolaas J H ^a,b   Tabima, D Marcela ^b   Specht, Patricia A C ^a   Tejero, Jesús ^b   Champion, Hunter C ^b,c   Kim Shapiro, Daniel B ^d   Baust, Jeff ^b   Mik, Egbert G ^a   Hildesheim, Mariana ^c   Stasch, Johannes Peter ^e,f   Becker, Eva Maria ^e,g   Truebel, Hubert ^e,g   Gladwin, Mark T ^b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST UNIVERSITY   (United States)

^e BAYER PHARMA AG   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; HEME; N(G) NITROARGININE METHYL ESTER; NITROGEN OXIDE; NITROPRUSSIDE SODIUM; OXYHEMOGLOBIN; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BLOOD TRANSFUSION; CELL FREE SYSTEM; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; INTRAVASCULAR HEMOLYSIS; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCAVENGING SYSTEM; THROMBOCYTE ACTIVATION; VASOCONSTRICTION;

BENZOATES; BIPHENYL COMPOUNDS; ENZYME ACTIVATION; FREE RADICAL SCAVENGERS; GUANYLATE CYCLASE; HUMANS; HYDROCARBONS, FLUORINATED; MORPHOLINES; NITRIC OXIDE; OXYHEMOGLOBINS; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; VASOCONSTRICTION;

EID: 84890539200     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5181     Document Type: Article

References (41)

1. Badejo AM, Jr., Nossaman VE, Pankey EA, Bhartiya M, Kannadka CB, Murthy SN, Nossaman BD, and Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol 299: H1153-H1159, 2010.
2. Baron DM, Yu B, Lei C, Bagchi A, Beloiartsev A, Stowell CP, Steinbicker AU, Malhotra R, Bloch KD, and Zapol WM. Pulmonary hypertension in lambs transfused with stored blood is prevented by breathing nitric oxide. Anesthesiology 116: 637-647, 2012.
3. Bourque SL, Whittingham HA, Brien SE, Davidge ST, and Adams MA. Role of endothelin-1 in the hyper-responsiveness to nitrovasodilators following acute NOS inhibition. Br J Pharmacol 165: 1992-1999, 2012.
4. Derbyshire ER and Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem 81: 533-559, 2012.
5. Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C, Reynolds H, Azarov I, Frizzell S, Meyer EM, Donnenberg AD, Qu L, Triulzi D, Kim-Shapiro DB, and Gladwin MT. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 124: 465-476, 2011.
6. Doyle MP and Hoekstra JW. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem 14: 351-358, 1981.
7. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, and Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350: 886-895, 2004.
8. Heim JM, Gottmann K, Weil J, Haufe MC, and Gerzer R. Is cyclic GMP a clinically useful marker for ANF action Z Kardiol 77 Suppl 2: 41-46, 1988.
9. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, and Gladwin MT. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109: 3088-3098, 2007.
10. Hu W, Jin R, Zhang J, You T, Peng Z, Ge X, Bronson RT, Halperin JA, Loscalzo J, and Qin X. The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood 116: 1613-1622, 2010.
11. Huang Z, Louderback JG, Goyal M, Azizi F, King SB, and Kim-Shapiro DB. Nitric oxide binding to oxygenated hemoglobin under physiological conditions. Biochim Biophys Acta 1568: 252-260, 2001.
12. Ignarro LJ, Byrns RE, Buga GM, and Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 61: 866-879, 1987.
13. Jeffers A, Gladwin MT, and Kim-Shapiro DB. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic Biol Med 41: 1557-1565, 2006.
14. Kemp-Harper B, Luk J, Favaloro JL, Stasch JP, and Schmidt HHHW. Oxidised sGC: A novel therapeutic target in the vasculature. BMC Pharmacol 7: S5, 2007.
15. Kim-Shapiro DB, Schechter AN, and Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 26: 697-705, 2006.
16. Knorr A, Hirth-Dietrich C, Alonso-Alija C, Harter M, Hahn M, Keim Y, Wunder F, and Stasch JP. Nitric oxideindependent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58: 71-80, 2008.
17. Mendes-Silverio CB, Leiria LO, Morganti RP, Anhe GF, Marcondes S, Monica FZ, De Nucci G, and Antunes E. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway. PLoS One 7: E47223, 2012.
18. Moncada S and Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993.
19. Nagasu H, Satoh M, Kidokoro K, Nishi Y, Channon KM, Sasaki T, and Kashihara N. Endothelial dysfunction promotes the transition from compensatory renal hypertrophy to kidney injury after unilateral nephrectomy in mice. Am J Physiol Renal Physiol 302: F1402-F1408, 2012.
20. Natanson C, Kern SJ, Lurie P, Banks SM, and Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: A meta-analysis. JAMA 299: 2304-2312, 2008.
21. Ott IM, Alter ML, von Websky K, Kretschmer A, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Stasch JP, and Hocher B. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade. PLoS One 7: E42623, 2012.
22. Palmer RM, Ferrige AG, and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1987.
23. Pankey EA, Bhartiya M, Badejo AM, Jr., Haider U, Stasch JP, Murthy SN, Nossaman BD, and Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am J Physiol Heart Circ Physiol 300: H792-H802, 2011.
24. Raat NJ, Verhoeven AJ, Mik EG, Gouwerok CW, Verhaar R, Goedhart PT, de Korte D, and Ince C. The effect of storage time of human red cells on intestinal microcirculatory oxygenation in a rat isovolemic exchange model. Crit Care Med 33: 39-45, 2005.
25. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, III, Schechter AN, and Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8: 1383-1389, 2002.
26. Roger S, Paysant J, Badier-Commander C, Cordi A, Verbeuren TJ, and Feletou M. Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase. Vascul Pharmacol 53: 281-287, 2010.
27. Rother RP, Bell L, Hillmen P, and Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 293: 1653-1662, 2005.
28. Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JGt, Hannoush H, Goldsmith JC, Gladwin MT, and Gordeuk VR. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation 124: 1452-1460, 2011.
29. Schmidt HHHW, Schmidt PM, and Stasch JP. NO-and haem-independent soluble guanylate cyclase activators. In: Handbook of Experimental Pharmacology. cGMP Generators, Effectors and Therapeutic Implications, edited by Hofmann F, Schmidt HHHW, and Stasch JP. Berlin-Heidelberg: Springer-Verlag, 2009, pp. 309-339.
30. Schmidt P, Schramm M, Schroder H, and Stasch JP. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol 468: 167-174, 2003.
31. Silverman TA and Weiskopf RB. Hemoglobin-based oxygen carriers: Current status and future directions. Anesthesiology 111: 946-963, 2009.
32. Stasch JP, Dembowsky K, Perzborn E, Stahl E, and Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vivo studies. Br J Pharmacol 135: 344-355, 2002.
33. Stasch JP, Kazda S, and Neuser D. Different effects of ANP and nitroprusside on cyclic GMP extrusion of isolated aorta. Eur J Pharmacol 174: 279-282, 1989.
34. Stasch JP, Pacher P, and Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123: 2263-2273, 2011.
35. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, and Wunder F. NO-and haem-independent activation of soluble guanylyl cyclase: Molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783, 2002.
36. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, HS AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, and Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561, 2006.
37. Surmeli NB and Marletta MA. Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat. Chembiochem 13: 977-981, 2012.
38. Tsai EJ, Liu Y, Koitabashi N, Bedja D, Danner T, Jasmin JF, Lisanti MP, Friebe A, Takimoto E, and Kass DA. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res 110: 295-303, 2012.
39. Vermeulen Windsant IC, Hanssen SJ, Buurman WA, and Jacobs MJ. Cardiovascular surgery and organ damage: Time to reconsider the role of hemolysis. J Thorac Cardiovasc Surg 142: 1-11, 2011.
40. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, and Peters H. Enhancing cGMP in experimental progressive renal fibrosis: Soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol Renal Physiol 290: F167-F176, 2006.
41. Wood KC, Hsu LL, and Gladwin MT. Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radic Biol Med 44: 1506-1528, 2008.